Myeloperoxidase, carnitine, and derivatives of reactive oxidative metabolites in heart failure with preserved versus reduced ejection fraction: A meta-analysis

Chenille N Wong,Xi Yao Gui,Simon W Rabkin,Chenille N. Wong,Simon W. Rabkin
DOI: https://doi.org/10.1016/j.ijcard.2023.131657
IF: 4.039
2023-12-15
International Journal of Cardiology
Abstract:Background Understanding the pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF) continues to be challenging. Several inflammatory and metabolic biomarkers have recently been suggested to be involved in HFpEF. Objectives The purpose of this review was to synthesize the evidence on non-traditional biomarkers from metabolomic studies that may distinguish HFpEF from heart failure with reduced ejection fraction (HFrEF) and controls without HF. Methods A systematic search was conducted using Medline and PubMed with search terms such as "HFpEF" and "metabolomics", and a meta-analysis was conducted. Results Myeloperoxidase (MPO) levels were significantly ( p < 0.001) higher in HFpEF than controls without HF, but comparable ( p = 0.838) between HFpEF and HFrEF. Carnitine levels were significantly ( p < 0.0001) higher in HFrEF than HFpEF, but comparable ( p = 0.443) between HFpEF and controls without HF. Derivatives of reactive oxidative metabolites (DROMs) were not significantly ( p = 0.575) higher in HFpEF than controls without HF. Conclusion These data suggest that MPO is operative in HFpEF and HFrEF and may be a biomarker for HF. Furthermore, circulating carnitine levels may distinguish HFrEF from HFpEF.
cardiac & cardiovascular systems
What problem does this paper attempt to address?